Zhussipbek Mukhatayev, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitiligo | 3 | 2024 | 98 | 1.690 |
Why?
|
Pulmonary Fibrosis | 1 | 2024 | 507 | 0.700 |
Why?
|
Extracellular Matrix Proteins | 1 | 2024 | 829 | 0.690 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2024 | 3076 | 0.500 |
Why?
|
Antigens | 1 | 2020 | 1447 | 0.490 |
Why?
|
Fibroblasts | 1 | 2024 | 4091 | 0.450 |
Why?
|
Skin Diseases | 1 | 2021 | 1089 | 0.400 |
Why?
|
Autoimmune Diseases | 2 | 2021 | 2250 | 0.390 |
Why?
|
Melanocytes | 2 | 2024 | 512 | 0.320 |
Why?
|
Autoimmunity | 2 | 2024 | 1370 | 0.230 |
Why?
|
Immune Tolerance | 2 | 2024 | 2299 | 0.220 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2024 | 499 | 0.150 |
Why?
|
Food Hypersensitivity | 1 | 2024 | 692 | 0.140 |
Why?
|
Extracellular Matrix | 1 | 2024 | 1726 | 0.140 |
Why?
|
Transforming Growth Factor beta | 1 | 2024 | 1956 | 0.130 |
Why?
|
Interleukin-10 | 1 | 2020 | 1174 | 0.120 |
Why?
|
Tuberous Sclerosis | 1 | 2021 | 1030 | 0.110 |
Why?
|
Animals | 7 | 2024 | 167940 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1442 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2021 | 2536 | 0.100 |
Why?
|
Skin | 2 | 2020 | 4468 | 0.090 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9531 | 0.080 |
Why?
|
Anti-HIV Agents | 1 | 2022 | 4492 | 0.070 |
Why?
|
Immunotherapy | 1 | 2021 | 4637 | 0.060 |
Why?
|
HIV-1 | 1 | 2022 | 6850 | 0.060 |
Why?
|
Kazakhstan | 1 | 2022 | 19 | 0.050 |
Why?
|
Quality of Life | 1 | 2024 | 13300 | 0.050 |
Why?
|
Nevirapine | 1 | 2022 | 273 | 0.050 |
Why?
|
Humans | 8 | 2024 | 760261 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7400 | 0.050 |
Why?
|
Zidovudine | 1 | 2022 | 624 | 0.050 |
Why?
|
Neomycin | 1 | 2019 | 93 | 0.040 |
Why?
|
Ampicillin | 1 | 2019 | 141 | 0.040 |
Why?
|
Mice | 3 | 2021 | 81216 | 0.040 |
Why?
|
Pseudomonas | 1 | 2019 | 123 | 0.040 |
Why?
|
Bacteroides | 1 | 2019 | 165 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2022 | 859 | 0.040 |
Why?
|
Allergens | 1 | 2024 | 1399 | 0.030 |
Why?
|
HIV Infections | 1 | 2022 | 17159 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 1006 | 0.030 |
Why?
|
DNA, Bacterial | 1 | 2019 | 1455 | 0.030 |
Why?
|
Viral Load | 1 | 2022 | 3323 | 0.030 |
Why?
|
Feces | 1 | 2019 | 1466 | 0.030 |
Why?
|
Administration, Oral | 1 | 2019 | 4044 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 3023 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7345 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18134 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29950 | 0.010 |
Why?
|
Female | 2 | 2021 | 391011 | 0.010 |
Why?
|
Male | 1 | 2019 | 359413 | 0.000 |
Why?
|